Antigen News and Research

RSS

COVID-19 vaccination of lactating mothers elicits specific IgA antibodies in breast milk

A new study, released on the medRxiv* preprint server, examines the presence of SARS-CoV-2-specific IgA in human milk and its association with the protection of breastfed infants against the disease.

16 Apr 2021

Ovarian follicular function unaffected by SARS-CoV-2 infection or Pfizer vaccine, study finds

A new study by researchers in Jerusalem indicates that while specific antibodies to the virus are present in both serum and ovarian follicles following infection or vaccination, there is no apparent adverse effect on follicular function as a result.

15 Apr 2021

SARS-CoV-2 mutations impact T-cell recognition of virus

A new research paper posted to the bioRxiv preprint server deals with the impact of these mutations on adaptive cellular immunity.

14 Apr 2021

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.

14 Apr 2021

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

A new research paper posted to the medRxiv* preprint server describes the changes in genomic sequence observed during the course of infection in a patient on the drug tacrolimus, along with steroids, both potent immunosuppressants, and who also received convalescent plasma treatment. These mutations were observed to occur within three weeks from infection.

14 Apr 2021

Expanding risk assessment parameters improves prediction of waitlist mortality for liver transplants

The top priority in the field of transplantation is to ensure that donor organs are allocated to the patients with the greatest need.

13 Apr 2021

Measurable antibody response to mRNA COVID-19 vaccine in elderly care home residents

A new preprint research paper posted to the medRxiv* server explores the antibody response to COVID-19 vaccines in elderly residents of nursing homes in the USA. As of March 2021, there have been over 1.4 million infections from SARS-CoV-2 and over 175,000 deaths related to the pandemic among nursing home residents in the country.

13 Apr 2021

CityMD experience during the coronavirus pandemic in New York City

Limiting SARS-CoV-2 transmission requires an infected person to quarantine themselves for at least two weeks. New research published on the medRxiv* server highlights the vital role urgent care centers play during the COVID-19 pandemic in New York.

13 Apr 2021

Broadly cross-reactive antibody to SARS-CoV-2 RBD with robust resistance to mutational escape

A new study addresses an urgent need – namely, a therapeutic antibody directed specifically against a key SARS-CoV-2 antigen which is highly conserved among similar viruses, and is not easily bypassed by viral escape mutations.

12 Apr 2021

Researchers work to develop dual antigen COVID-19 vaccine candidate

A new study has been published on the medRxiv* preprint server, which focuses on the development of a dual-antigen COVID-19' T cell' vaccine. This vaccine is developed based on the expression of both S protein and nucleocapsid (N) protein of SARS-CoV-2, using a next-generation human adenovirus serotype 5 (Ad5) platform.

12 Apr 2021

CD40 drug before surgery can benefit patients with early-stage pancreatic cancer

Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study from researchers in the Abramson Cancer Center (ACC) at the University of Pennsylvania.

12 Apr 2021

mRNA-based COVID-19 vaccination during pregnancy provides passive SARS-CoV-2 immunity to neonates 16 days after first dose

Recently, a group of researchers analyzed 122 pregnant women and their neonates at the time of birth. All the women studied received 1 or both doses of a messenger RNA (mRNA)-based vaccine for COVID-19. Of the 122 women part of the study, 55 had received only the first dose of the vaccine while 67 women had received both doses of the mRNA vaccine by the time they gave birth; 85 women had received the Pfizer-BioNTech vaccine, and 37 women received the Moderna vaccine. The study is published on the preprint server, bioRxiv.

11 Apr 2021

L452R and Y453F SARS-CoV-2 mutations increase transmission and evade immunity

Mutations from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have created multiple variants. Some variants, such as those found in South Africa and Brazil, have caused concern for their potential to evade the immune response. While vaccination efforts are underway, the world is racing against the viruses’ ability to evolve under selective pressure.

11 Apr 2021

Does natural infection with SARS-CoV-2 offer more protection than a vaccine against new variants?

A new study demonstrates that vaccines may be less effective at countering the newer SARS-CoV-2 variants compared to natural infection.

9 Apr 2021

Serum and breast milk SARS-CoV-2 antibodies correlated in vaccinated mothers

A new study shows the correlation between serum levels of antibodies to SARS-CoV-2 and levels in breast milk following the vaccination of lactating women with a vaccine based on mRNA technology.

9 Apr 2021

Study reveals molecular mechanisms of drug resistance in Mycobacterium tuberculosis

A consortium of researchers from Russia, Belarus, Japan, Germany and France led by a Skoltech scientist have uncovered the way in which Mycobacterium tuberculosis survives in iron-deficient conditions by utilizing rubredoxin B, a protein from a rubredoxin family that play an important role in adaptation to changing environmental conditions.

9 Apr 2021

Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial

A new preprint research paper posted to the medRxiv server reports the results of the first human trial of the prefusion stabilized SARS-CoV-2 spike vaccine MVC-COV1901 in Taiwan.

8 Apr 2021

Bispecific antibodies neutralize SARS-CoV-2 and its variants

A new bioRxiv preprint study led by Joshua Tan from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, involves generating bispecific antibodies using a new method cross-linking the antibodies with adjacent spike proteins using dual N-terminal domain/receptor binding domain specificity.

7 Apr 2021

Which SARS-CoV-2 spike mutants can evade T cell immunity?

A new study reports the capability of a new variant of the virus to escape specific cellular immunity, while possessing a higher binding affinity to the host cell binding receptor, the angiotensin-converting enzyme 2 (ACE2).

7 Apr 2021

Can limiting the priming dose of a SARS-CoV-2 vaccine improve immunity?

Researchers from Northwestern University and the University of Rochester in the U.S. addressed this question in their study. The researchers also explored whether the vaccines administered across the world could confer sterilizing immunity while preventing severe disease and death.

6 Apr 2021

Antigen News and Research

COVID-19 vaccination of lactating mothers elicits specific IgA antibodies in breast milk

Ovarian follicular function unaffected by SARS-CoV-2 infection or Pfizer vaccine, study finds

SARS-CoV-2 mutations impact T-cell recognition of virus

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

Expanding risk assessment parameters improves prediction of waitlist mortality for liver transplants

Measurable antibody response to mRNA COVID-19 vaccine in elderly care home residents

CityMD experience during the coronavirus pandemic in New York City

Broadly cross-reactive antibody to SARS-CoV-2 RBD with robust resistance to mutational escape

Researchers work to develop dual antigen COVID-19 vaccine candidate

CD40 drug before surgery can benefit patients with early-stage pancreatic cancer

mRNA-based COVID-19 vaccination during pregnancy provides passive SARS-CoV-2 immunity to neonates 16 days after first dose

L452R and Y453F SARS-CoV-2 mutations increase transmission and evade immunity

Does natural infection with SARS-CoV-2 offer more protection than a vaccine against new variants?

Serum and breast milk SARS-CoV-2 antibodies correlated in vaccinated mothers

Study reveals molecular mechanisms of drug resistance in Mycobacterium tuberculosis

Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial

Bispecific antibodies neutralize SARS-CoV-2 and its variants

Which SARS-CoV-2 spike mutants can evade T cell immunity?

Can limiting the priming dose of a SARS-CoV-2 vaccine improve immunity?

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics